Peabody C A, Thiemann S, Pigache R, Miller T P, Berger P A, Yesavage J, Tinklenberg J R
Neurobiol Aging. 1985 Summer;6(2):95-100. doi: 10.1016/0197-4580(85)90024-7.
Vasopressin peptides have been shown to facilitate learning and memory in both animals and humans; however, the effectiveness in humans is controversial. In a double blind parallel group study, 17 demented subjects (either Alzheimer's or alcoholic) were given either desglycinamide-9-arginine-8-vasopressin (DGAVP) 92 micrograms intranasally TID or an identical placebo for 1 week after having received 1 week of placebo. To our knowledge, this is the first report of DGAVP being used in subjects with dementia. The DGAVP group had a statistically significant improvement on the Buschke list learning of low imagery words. However, for various reasons discussed in the paper, we feel this finding needs to be replicated before any definite conclusions can be drawn. Since there were no other appreciable behavioral effects of this DGAVP regimen, our results should be considered negative. There was no evidence of any DGAVP-related adverse effects, except for possible weight gain.
血管加压素肽已被证明在动物和人类中均能促进学习和记忆；然而，其在人类中的有效性存在争议。在一项双盲平行组研究中，17名痴呆患者（阿尔茨海默病患者或酒精性痴呆患者）在接受了1周的安慰剂治疗后，被给予鼻内注射去甘氨酰胺 -9-精氨酸 -8-加压素（DGAVP）92微克，每日三次，持续1周，或给予相同的安慰剂。据我们所知，这是关于DGAVP用于痴呆患者的首次报告。DGAVP组在Buschke低意象词汇学习列表上有统计学意义的改善。然而，由于本文中讨论的各种原因，我们认为这一发现需要在得出任何明确结论之前进行重复验证。由于该DGAVP治疗方案没有其他明显的行为影响，我们的结果应被视为阴性。除了可能的体重增加外，没有证据表明存在任何与DGAVP相关的不良反应。
